---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Natural history, survival, and mortality"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Natural history, survival, and mortality. Topics: Enroll-HD: prospective observational natural history study, annual visits, and periodic data releases; TRACK-HD: 12-month changes in premanifest and early Huntington's disease; Rate of functional decline on Total Functional Capacity: cohort of 960 participants followed prospectively; Enroll-HD progression model: trajectories of functional, motor, and cognitive decline; 11 further topics. 15 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Enroll-HD: prospective observational natural history study, annual visits, and periodic data releases

> “Enroll-HD is now operating worldwide in 21 countries at 159 clinical sites across four continents”
> “Europe, North America, Latin America, and Australasia”
> “and has recruited almost 25,000 participants”
> “Central to the clinical research platform is the Enroll-HD study (NCT01574053), a prospective longitudinal observational study that collects natural history data in HD gene-expansion carriers (HDGECs) and non-HDGEC controls.”
> “The Enroll-HD platform has been designed with the benefit of experience gained from several foundational HD studies”
> “REGISTRY, PREDICT-HD, COHORT, and TRACK-HD/Track On-HD (12–16).”
> “At their annual study visit, each participant is required to complete a core battery of assessments; extended and optional assessments are completed at the discretion of the PI and participant, respectively (Table 2).”
> “PDSs are prepared from the Enroll-HD study database every 1–2 years and include a large majority of the collected variables.”

Source: [Sathe et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8416308/)

<a id="topic-2.2.1.3-2"></a>

### TRACK-HD: 12-month changes in premanifest and early Huntington's disease

> “TRACK-HD is a prospective observational study of Huntington's disease (HD) that examines disease progression in premanifest individuals carrying the mutant HTT gene and those with early stage disease.”
> “We report 12-month longitudinal changes, building on baseline findings.”
> “Whole-brain atrophy rates were 0·20% (95% CI 0·05-0·34; p=0·0071) per year higher in preHD participants and 0·60% (0·44-0·76; p<0·0001) in early HD patients, and caudate atrophy rates were 1·37% (0·99-1·75; p<0·0001) per year higher in preHD and 2·86% (2·34-3·39; p<0·0001) in early HD.”
> “Relative to controls, decline in cognition and quantitative motor function was detectable in both pre- and early HD, as was deterioration in oculomotor function in early HD.”

Source: [Tabrizi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21130037/)

<a id="topic-2.2.1.3-3"></a>

### Rate of functional decline on Total Functional Capacity: cohort of 960 participants followed prospectively

> “The annual rate of functional decline was measured using the Total Functional Capacity Scale (TFC) and the Independence Scale (IS) in 960 patients with definite HD followed prospectively for a mean of 18.3 months.”
> “The TFC score declined at a rate of 0.72 units/year (standard error [SE] 0.04) and the IS score declined at a rate of 4.52 units/year (SE 0.23).”

Source: [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/)

<a id="topic-2.2.1.3-4"></a>

### Enroll-HD progression model: trajectories of functional, motor, and cognitive decline

> “We included 8,071 Enroll-HD participants (mean baseline age: 51.4 years, 51.5% female) to develop a natural history progression model using baseline characteristics as predictive covariates.”
> “Our analysis revealed that TFC and TMS are best characterized by logistic-like trajectories while cognitive scores (SDMT and SWR) display an exponential-like decline (Figure 1, B and C).”
> “These results highlight the temporal differences in the rate of progression captured by different clinical end points and emphasize that individuals who exhibit rapid progression according to one clinical score may not necessarily exhibit fast progression according to another.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.1.3-5"></a>

### GENERATION HD1 placebo arm compared with Enroll-HD natural history on Total Functional Capacity

> “We observed that for the functional score (TFC), the progression during the trial aligns with the natural history progression, showing no sign of a relevant placebo response (Figure 4A).”
> “It is important to note that our analysis revealed that a placebo response initially leads to an improvement after baseline, but after accounting for this initial improvement, the rate of progression between the GENERATION HD1 placebo arm and Enroll-HD cohorts remained consistent.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.1.3-6"></a>

### Age at onset and prodromal phase

> “The mean age of onset is approximately 45 years”
> “About two thirds of individuals first present with neurologic manifestations; others present with psychiatric changes.”
> “These subtle changes can occur as early as 15-20 years prior to the clinical onset of manifest HD.”
> “In approximately 25% of individuals with HD, the onset is delayed until after age 50 years, with some after age 70 years”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.3-7"></a>

### Prodromal change detected before diagnosis: PREDICT-HD

> “1078 individuals with a CAG expansion were included in this analysis. Participants were followed up for a mean of 5·1 years (SD 3·3, range 0·0-12·0). 225 (21%) of these participants received a motor diagnosis of Huntington's disease during the study.”

Source: [Paulsen et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25453459/)

> “This work showed that measurable brain and behavioral changes can be detected up to 15 years before an HD diagnosis.”

Source: [NINDS (2026)](https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease)

<a id="topic-2.2.1.3-8"></a>

### Disease stages: Huntington's Disease Integrated Staging System

> “The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's disease genetic mutation without any detectable pathological change) by using a genetic definition of Huntington's disease. Huntington's disease progression is then marked by measurable indicators of underlying pathophysiology (Stage 1), a detectable clinical phenotype (Stage 2), and then decline in function (Stage 3).”

Source: [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

<a id="topic-2.2.1.3-9"></a>

### Progression in premanifest and early disease: TRACK-HD

> “In the preHD-B group, several quantitative motor and cognitive tasks showed significantly increased rates of decline at 36 months, compared with controls, whereas few had at 24 months.”

Source: [Tabrizi et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23664844/)

> “For either score, initial progression age and then acceleration rate were highly CAG repeat length dependent. The acceleration continues through at least stage II disease.”

Source: [Langbehn et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6692683/)

<a id="topic-2.2.1.3-10"></a>

### Survival after onset and age at death

> “In late stages of HD, motor disability becomes severe, and the individual is often totally dependent, mute, and incontinent. The median survival time after onset is 15 to 18 years (range: 5 to >25 years). The average age at death is 54 to 58 years”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “For these fully ascertained subjects, the range, mean, SD, and median of duration values were 0–46, 15.4, 6.8, and 15 years, respectively.”
> “We found that, as with clinical onset, HD age at death is determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation's length.”

Source: [Keum et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4746370/)

<a id="topic-2.2.1.3-11"></a>

### Mortality relative to the general population: UK cohort

> “The KM survival curve (Figure 1) shows a median survival time of 12.4 years (95% CI 10.6–15.2). Median age at death in individuals with HD and controls was 71 (IQR 59–79) and 81 (IQR 73–86) years, respectively. Individuals with HD were at 4.5 times greater risk of death than controls (hazard ratio 4.51, 95% CI 3.36–6.06, p < 0.001) after multivariable adjustment of baseline covariates (Figure S1).”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.3-12"></a>

### Age at death and causes of death: Norwegian national registries

> “Mean age at death for individuals with HD was found to be 63.9 years (NCDR) and 61.7 years (CRD), compared to a mean of 76.9 years in the general population (NCDR).”
> “In 73.5% of individuals with HD, the underlying cause of death was HD, followed by cardiovascular diseases, cancer and respiratory diseases. The most common immediate cause of death was respiratory diseases (44.2%). Suicide was a more common cause of death in the population with HD (2.3%) compared to the general population (1.3%).”

Source: [Solberg et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5870025/)

<a id="topic-2.2.1.3-13"></a>

### Causes of death: aspiration pneumonia

> “Two hundred twenty four charts of deceased HD patients were reviewed, of which 216 (111/104 male/female, one unknown) had records available, 147 listed a cause of death (Table 1), which was pneumonia in 81 (55%) cases.”
> “The conclusion is that the majority (86.8%) of our HD patients where the cause of death could be identified died from aspiration pneumonia.”

Source: [Heemskerk and Roos (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269785/)

<a id="topic-2.2.1.3-14"></a>

### Suicide and suicidal ideation

> “Incidence of suicidal ideation, suicide attempt, and suicide are higher among those with HD relative to the non-HD population.”

Source: [Kachian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30875675/)

> “At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation.”
> “The 4-year cumulative incidence of suicidal ideation was 9.9%.”

Source: [Hubers et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23876196/)

> “The critical periods for suicide risk are just prior to receiving a diagnosis and later, when affected individuals experience a loss of independence”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.3-15"></a>

### Juvenile Huntington's disease: progression and survival

> “Disease progression of JHD is faster compared to AOHD and the disease duration is shorter, particularly in case of higher CAG repeat lengths.”

Source: [Oosterloo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307030/)

> “Disease progression was more rapid in juvenile Huntington's disease (n=14) than in adult-onset Huntington's disease (n=52; generalised estimating equation model, p=0·0003). Of 121 deceased patients, median survival was shorter in the juvenile Huntington's disease (n=17) cohort than in adult-onset Huntington's disease (n=104) cohort (hazard ratio 2·18 [95% CI 1·08-4·40]; p=0·002).”

Source: [Fusilli et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30243861/)

Additional sources: [Rodrigues and Ferreira (2017b)](https://pubmed.ncbi.nlm.nih.gov/29052699/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
